


WHO GUIDELINES FOR THE

Treatment of *Chlamydia trachomatis*



WHO GUIDELINES FOR THE

Treatment of *Chlamydia trachomatis*



World Health
Organization

WHO Library Cataloguing-in-Publication Data

WHO guidelines for the treatment of Chlamydia trachomatis.

Contents: Web annex D: Evidence profiles and evidence-to-decision framework -- Web annex E: Systematic reviews -- Web annex F: Summary of conflicts of interest

1.Chlamydia trachomatis. 2.Chlamydia Infections - drug therapy.
3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization.

ISBN 978 92 4 154971 4 (NLM classification: WC 600)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

Acknowledgements	iii
Abbreviations and acronyms	iv
Executive summary	1
Overview of the guidelines for the prevention, treatment and management of STIs	6
STI epidemiology and burden	6
Why new guidelines for the prevention, treatment and management of STIs?	6
Approach to the revision of STI guidelines	8
References	9
WHO guidelines for the treatment of <i>Chlamydia trachomatis</i>	10
1. Introduction	10
1.1 Epidemiology, burden and clinical considerations	10
Clinical presentation	10
Laboratory diagnosis	11
1.2 Rationale for new recommendations	11
1.3 Objectives	11
1.4 Target audience	11
1.5 Structure of the guidelines	11
2. Methods	12
2.1 Guideline Development Group (GDG)	12
2.2 Questions and outcomes	12
2.3 Reviews of the evidence	12
2.4 Making recommendations	13
2.5 Management of conflicts of interest	14
3. Dissemination, updating and implementation of the guidelines	15
3.1 Dissemination	15
3.2 Updating the STI guidelines and user feedback	15
3.3 Implementation of the WHO guidelines for the treatment of <i>C. trachomatis</i>	15
Adaptation, implementation and monitoring	15
Identifying and procuring STI drugs	16
4. Recommendations for treatment of chlamydial infections	17
4.1 Uncomplicated genital chlamydia	17
Recommendation 1	17
4.2 Anorectal chlamydial infection	18
Recommendation 2	18
4.3 Chlamydial infection in pregnant women	19
Recommendation 3a	19
Recommendation 3b	19
Recommendation 3c	19
4.4 Lymphogranuloma venereum (LGV)	20
Recommendation 4	20

CONTENTS (CONTINUED)

4.5 Ophthalmia neonatorum	20
Recommendation 5	20
Recommendation 6	21
Recommendation 7	21
References	22
Annex A: STI guideline development teams	23
Annex B: Detailed methods for guideline development	32
Questions and outcomes	32
Review of the evidence	35
Applying the GRADE approach to making the recommendations	38
Annex C: Lists of references for reviewed evidence	39
Recommendation 1	39
Recommendation 2	40
Recommendation 3a, 3b, 3c	41
Recommendation 4	42
Recommendation 5	43
Recommendations 6 and 7	43

Web annexes available at:

www.who.int/reproductivehealth/publications/rtis/chlamydia-treatment-guidelines/en/

Web annex D: Evidence profiles and evidence-to-decision frameworks

Web annex E: Systematic reviews for chlamydia guidelines

Web annex F: Summary of conflicts of interest

ACKNOWLEDGEMENTS

The Department of Reproductive Health and Research at the World Health Organization (WHO) would like to thank the members of the STI Guideline Development Group for their consistent availability and commitment to making these guidelines possible. The Department is also grateful to the STI External Review Group for peer reviewing these guidelines, and appreciates the contribution of the WHO Steering Committee. The names of the members of each group are listed below, with full details provided in Annex A.

Special thanks to Dr Nancy Santesso, the guideline methodologist who also led the systematic review process, for her hard work and firm commitment of the guideline development process. We also thank the members of the Systematic Review Team from McMaster University.

We appreciate the overall support of the WHO Guideline Review Committee Secretariat during the guideline development process, with grateful thanks to Dr Susan Norris.

We thank Theresa Ryle for the administrative support and 400 Communications for assistance with the guideline design and layout. This guideline document was edited by Ms Jane Patten, of Green Ink, United Kingdom.

Dr Teodora Wi led the guideline development process and Dr Nathalie Broutet co-led the process under the supervision of Dr James Kiarie and leadership of Dr Ian Askew. Lee Sharkey provided support during the guideline development process.

FUNDING

The preparation and printing of the guidelines were funded exclusively by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). No external source of funding was solicited or utilized.

CONTRIBUTORS TO WHO GUIDELINES FOR THE TREATMENT OF *CHLAMYDIA TRACHOMATIS*

STI Guideline Development Group (GDG):

Chairpersons: Judith Wasserheit, Holger Schünemann and Patricia Garcia

Members: Yaw (Sax) Adu-Sarkodie, Andrew Amato, Gail Bolan, John Changalucha, Xiang-Sheng Chen, Harrel Chesson, Craig Cohen, Francisco Garcia, Suzanne Garland, Sarah Hawkes, Mary Higgins, King Holmes, Jeffrey Klausner, David Lewis, Nicola Low, David Mabey, Angelica Espinosa Miranda, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Keith Radcliffe, Ulugbek Sabirov, Judith Stephenson, Richard Steen, Magnus Unemo, Bea Vuylsteke, Anna Wald, Thomas Wong and Kimberly A. Workowski

STI GDG working group for chlamydia:

Andrew Amato, Harrell Chesson, Craig Cohen, Patricia Garcia, Nicola Low, David Mabey, Angelica Miranda, Francis Ndowa, Keith Radcliffe, Judith Stephenson, Magnus Unemo, Bea Vuylsteke and Judith Wasserheit

STI External Review Group: Laith Abu-Raddad, Adele Benaken-Schwartz, Mircea Betiu, Anupong Chitwarakorn, Anjana Das, Carolyn Deal, Margaret Gale-Rowe, William M. Geisler, Amina El Kettani, Mizan Kiros, Ahmed Latif, Philippe Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, Khantanouvieng Sayabounthavong and Aman Kumar Singh

WHO Steering Committee:

WHO regional offices: Massimo Ghidinelli, Hamida Khattabi, Lali Khotenashvili, Ornella Lincetto Ying-Ru Lo, Frank Lule and Razia Pendse

WHO headquarters: Moazzam Ali, Avni Amin, Rachel Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, Mario Festin, Mary Lyn Gaffield, Antonio Gerbase, Sami Gottlieb, Silvio Paolo Mariotti, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, Igor Toskin and Marco Vitoria

WHO STI Secretariat: Ian Askew, Teodora Elvira Wi (lead, development of the guidelines), Nathalie Broutet (co-lead, development of the guidelines), James Kiarie and Lee Sharkey

Systematic Review Team: Nancy Santesso (lead), Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, Kristie Poole, Nicole Schwab, Matthew Ventresca, Yuan Zhang and Andrew Zikic (members)

Methodologist: Nancy Santesso.

ABBREVIATIONS AND ACRONYMS

AIDS	acquired immune deficiency syndrome
AMR	antimicrobial resistance
DALY	disability-adjusted life year
DFA	direct fluorescent antibody
DOI	declaration of interests
ELISA	enzyme-linked immunosorbent assays
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GUD	genital ulcer disease
HIV	human immunodeficiency virus
HPV	human papillomavirus
HRP	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction
HSV-2	herpes simplex virus type 2
LGV	lymphogranuloma venereum
MSH	Management Sciences for Health
MSM	men who have sex with men
NAATs	nucleic acid amplification tests (NAATs)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27190

